← Back to Search

1 for Alopecia

Phase 2
Waitlist Available
Research Sponsored by Mitos Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessments occur weekly during treatment and follow-up assessments occur for 12 weeks following treatment.
Awards & highlights

Study Summary

Hair loss occurs commonly as a result of radiotherapy administered to the brain, and this can contribute to the distress and social isolation of patients with advanced cancer. In this study a topical gel will be applied directly to the scalp during each dose of radiotherapy. The goal is to determine to what extent the experimental drug is successful in lessening the hair loss.

Eligible Conditions
  • Alopecia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessments occur weekly during treatment and follow-up assessments occur for 12 weeks following treatment.
This trial's timeline: 3 weeks for screening, Varies for treatment, and assessments occur weekly during treatment and follow-up assessments occur for 12 weeks following treatment. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Effectiveness will be based on a comparison of hair retention scores between MTS-01 and placebo.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: 1Experimental Treatment1 Intervention
MTS-01 (7% Tempol gel)
Group II: 2Placebo Group1 Intervention
Vehicle

Find a Location

Who is running the clinical trial?

Mitos PharmaceuticalsLead Sponsor
1 Previous Clinical Trials
16 Total Patients Enrolled
1 Trials studying Alopecia
16 Patients Enrolled for Alopecia
James Metz, MDStudy ChairUniversity of Pennsylvania
1 Previous Clinical Trials
2,000 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
2008. "Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00801086.
All > Androgenetic Alopecia
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top